Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment

Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is a novel oral multikinase inhibitor that blocks the activity of several protein kinases. However, few guidelines exist for novel biomarkers to select patients who will likely benefit from regorafenib treatment. Metastatic colore...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ther Adv Med Oncol
Главные авторы: Lee, Min-Sang, Cho, Hee Jin, Hong, Jung Yong, Lee, Jeeyun, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Cho, Yong Beom, Kim, Seung Tae
Формат: Artigo
Язык:Inglês
Опубликовано: SAGE Publications 2020
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7649869/
https://ncbi.nlm.nih.gov/pubmed/33224274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920965842
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы